Skip to main content
  • ASM Journals
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Latest Articles
    • COVID-19 Research and News from ASM Journals
    • mSphere of Influence: Commentaries from Early Career Microbiologists
    • Archive
  • Topics
    • Applied and Environmental Science
    • Clinical Science and Epidemiology
    • Ecological and Evolutionary Science
    • Host-Microbe Biology
    • Molecular Biology and Physiology
    • Therapeutics and Prevention
  • For Authors
    • Getting Started
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About mSphere
    • Editor in Chief
    • Board of Editors
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • ASM Journals
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
mSphere
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Latest Articles
    • COVID-19 Research and News from ASM Journals
    • mSphere of Influence: Commentaries from Early Career Microbiologists
    • Archive
  • Topics
    • Applied and Environmental Science
    • Clinical Science and Epidemiology
    • Ecological and Evolutionary Science
    • Host-Microbe Biology
    • Molecular Biology and Physiology
    • Therapeutics and Prevention
  • For Authors
    • Getting Started
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About mSphere
    • Editor in Chief
    • Board of Editors
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
Opinion/Hypothesis | Therapeutics and Prevention

Questionable Efficacy of Therapeutic Antibodies in the Treatment of Anthrax

Jean-Nicolas Tournier, Clémence Rougeaux, Fabrice V. Biot, Pierre L. Goossens
Patricia A. Bradford, Editor
Jean-Nicolas Tournier
aInstitut de Recherche Biomédicale des Armées, Bacteriology, Anti-infectious Biotherapies, and Immunity Unit, Brétigny-sur-Orge, France
bInstitut Pasteur, Viral Genomics and Vaccination Unit, CNRS UMR-3569, Paris, France
cNational Reference Center for Anthrax (CNR-LE Charbon), Brétigny-sur-Orge, France
dEcole du Val-de-Grâce, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jean-Nicolas Tournier
Clémence Rougeaux
aInstitut de Recherche Biomédicale des Armées, Bacteriology, Anti-infectious Biotherapies, and Immunity Unit, Brétigny-sur-Orge, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabrice V. Biot
aInstitut de Recherche Biomédicale des Armées, Bacteriology, Anti-infectious Biotherapies, and Immunity Unit, Brétigny-sur-Orge, France
cNational Reference Center for Anthrax (CNR-LE Charbon), Brétigny-sur-Orge, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Fabrice V. Biot
Pierre L. Goossens
aInstitut de Recherche Biomédicale des Armées, Bacteriology, Anti-infectious Biotherapies, and Immunity Unit, Brétigny-sur-Orge, France
eInstitut Pasteur, Yersinia Unit, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia A. Bradford
Antimicrobial Development Specialists, LLC
Roles: Editor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/mSphere.00282-19
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

DOI 
https://doi.org/10.1128/mSphere.00282-19
PubMed 
31217301

Published By 
American Society for Microbiology Journals
History 
  • Published online June 19, 2019.

Copyright & Usage 
Copyright © 2019 Tournier et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
Editors and / or Reviewers 
  • Patricia A. Bradford, Editor, Antimicrobial Development Specialists, LLC

Author Information

  1. Jean-Nicolas Tourniera,b,c,d,
  2. Clémence Rougeauxa,
  3. Fabrice V. Biota,c and
  4. Pierre L. Goossensa,e
  1. aInstitut de Recherche Biomédicale des Armées, Bacteriology, Anti-infectious Biotherapies, and Immunity Unit, Brétigny-sur-Orge, France
  2. bInstitut Pasteur, Viral Genomics and Vaccination Unit, CNRS UMR-3569, Paris, France
  3. cNational Reference Center for Anthrax (CNR-LE Charbon), Brétigny-sur-Orge, France
  4. dEcole du Val-de-Grâce, Paris, France
  5. eInstitut Pasteur, Yersinia Unit, Paris, France
  • Address correspondence to Jean-Nicolas Tournier, jntournier.irba{at}gmail.com.
  • Citation Tournier J-N, Rougeaux C, Biot FV, Goossens PL. 2019. Questionable efficacy of therapeutic antibodies in the treatment of anthrax. mSphere 4:e00282-19. https://doi.org/10.1128/mSphere.00282-19.

View Abstract

Article usage

Article usage: June 2019 to January 2021

Rendering graph...
AbstractFullPdf
Jun 20193918483
Jul 201947531
Aug 2019122819
Sep 201942617
Oct 201912412
Nov 201934018
Dec 20191267
Jan 20207359
Feb 202013820
Mar 202003112
Apr 202065023
May 202025511
Jun 20203399
Jul 20200367
Aug 20200332
Sep 202003612
Oct 202064210
Nov 20202297
Dec 20205578
Jan 202132511
PreviousNext
Back to top
Download PDF
Citation Tools
Questionable Efficacy of Therapeutic Antibodies in the Treatment of Anthrax
Jean-Nicolas Tournier, Clémence Rougeaux, Fabrice V. Biot, Pierre L. Goossens
mSphere Jun 2019, 4 (3) e00282-19; DOI: 10.1128/mSphere.00282-19

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print
Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this mSphere article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Questionable Efficacy of Therapeutic Antibodies in the Treatment of Anthrax
(Your Name) has forwarded a page to you from mSphere
(Your Name) thought you would be interested in this article in mSphere.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Questionable Efficacy of Therapeutic Antibodies in the Treatment of Anthrax
Jean-Nicolas Tournier, Clémence Rougeaux, Fabrice V. Biot, Pierre L. Goossens
mSphere Jun 2019, 4 (3) e00282-19; DOI: 10.1128/mSphere.00282-19
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • OPINION/HYPOTHESIS
    • IS THE PA COMPONENT OF THE TOXINS THE JUDICIOUS THERAPEUTIC TARGET?
    • REEXAMINING ANTI-PA ANTIBODY EFFECTS AND TOXIN PATHOGENESIS
    • WHAT WENT WRONG WITH ANTI-PA ANTIBODY EVALUATION?
    • WHERE TO GO NOW?
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

anthrax
antitoxins
monoclonal antibodies
protective antigen
toxins

Related Articles

Cited By...

About

  • About mSphere
  • Board of Editors
  • Policies
  • For Reviewers
  • For the Media
  • Embargo Policy
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Author Warranty
  • Types of Articles
  • Getting Started
  • Ethics
  • Contact Us

Follow #mSphereJ

@ASMicrobiology

       

 

Website feedback

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Online ISSN: 2379-5042